OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
March 02, 2015
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
While the skin offers an alternative route of administration for local and systemic drug delivery, developing semi-solid dosage forms can be a challenge.
A General Chapter on mAbs will be published in USP-NF as biologics increase their role in healthcare.
It is vital that companies involved in the manufacturing and handling of cytotoxic drugs ensure that staff are given the highest possible levels of protection.
February 27, 2015
FDA announced that it would postpone a meeting that would be critical for the advancement of Celltrion’s Remicade biosimilar in the US.
February 25, 2015
Remsima will now be available for patients in 12 additional countries in the European Union.
Enclosures contain powders and particulates during hazardous drug manipulation.
February 24, 2015
Aprecia Pharmaceuticals' new facility in Ohio will create 150 jobs.
February 23, 2015
Bristol-Myers Squibb announced that it reached an agreement to acquire Flexus Biosciences and has entered into a $309-million partnership with Rigel Pharmaceuticals.
Celltrion announced that its Remicade biosimilar, Rensima, could save France, Italy, and the UK up to €336 million in costs to treat Crohn’s disease.